Department of Molecular Oncology
Department head: Professor Ragnhild A. Lothe
Deputy department head: Professor Rolf I. Skotheim
Laboratory manager: Professor Guro E. Lind
Department administrative consultants: Mona Hagen and Linda Uv Mjøen
Project groups in the Lothe lab:
|Cell signalling||Computational Oncology|
As a research department within the OUH Comprehensive Cancer Centre, it is our responsibility and goal to accomplish high quality and interdisciplinary biomedical research for improved precision medicine and management of cancer patients.
Our main research programs are devoted to colorectal cancer and prostate cancer (Link), and we have a longstanding project portfolio also on other solid tumor types. Our expertise in biomedical research spans several disciplines from cell biology to translational research, including also active clinical research collaborations, and we have a broad range of advanced technologies established in-lab (Link). The department scientists are inventors of several biomedical patents and active innovation projects.
Lothe lab – genetics, genomics, cell signaling, colorectal cancer, MPNST, tumor heterogeneity, pharmacogenomics, biomarkers
Skotheim lab – genome biology, transcript variation, tumor heterogeneity, prostate cancer, testicular cancer, bioinformatics
Lind lab – epigenetics, genetics, GI-cancers, bladder cancer, early detection, monitoring
All three group leaders are adjunct professors at the University of Oslo and are affiliated with the Institute for Clinical Medicine, the Institute for Biosciences and the Institute for Informatics. We aim to complete at least 3 academic degrees annually, and since the inauguration of the Department in 2006, 59 MSc/PhD degrees have successfully been defended.
The research groups are partners of the K. G. Jebsen Colorectal Cancer Research Centre (led by Prof. Lothe), the OUH priority area for colorectal cancer, the Norwegian Cancer Genomics Consortium, the European network for study on Cholangiocarcinoma, and the Global Testicular Cancer Consortium.